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Correlation Between Osteoporosis and Vascular Calcification in the Elderly
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Abstract Elderly osteoporosis and vascular calcification are both degenerative diseases associated with aging．They are one of the
main health problems in the aging society．Ｒecently，many studies have revealed the positive correlation between osteoporosis and vascular
calcification in the elderly． This paper reviews the relationships of two diseases from epidemiology，risk factors，pathogenesis and clinical
treatment and provide the theoretical reference foundation for further mechanism research and clinical treatment and seeks new therapeutic
targets．





















全世界约有 1 /3的女性和 1 /5的男性被不同程度的骨
质疏松所困扰［3］。一项关于中国 2010－2050 年骨质
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疏松所致骨折发生率和医疗费用的研究，估计目前中



































































































ＲANKL相结合，从而阻断 ＲANK 和 ＲANKL 的结合，
进而抑制破骨细胞的成熟与骨吸收的增加。可见，维
持 OPG /ＲANKL /ＲANK 系统的平衡能保持骨骼的正
常代谢，抑制骨质疏松等骨骼疾病的发生。不仅如
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Progress in Treatment of Left Ventricular Aneurysm after Myocardial Infarction
ZHU Xiao，ZHENG Jiankang，GOU Junqi，ZENG Wei，L Zhan
(The First Affiliated Hospital of North Sichuan Medical College，Nanchong 637000，Sichuan，China)
Abstract Left ventricular aneurysm is a serious complication of acute myocardial infarction．It often occurs in the left ventricular apex
and is frequently associated with nausea，arrhythmia，heart failure，left ventricular thrombus，cardiac rupture and even life-threatening
complications．Medical treatment for left ventricular aneurysm is almost ineffective，and the 10-year survival rate of untreated patients is only
18%．With the development of medicine，therapeutic strategy for left ventricular aneurysm is also changing．This paper reviews the progress in
the treatment of left ventricular aneurysm．
Key words Acute myocardial infarction;Left ventricular aneurysm;Treatment
室壁瘤(VA)又称室壁膨胀瘤，是急性心肌梗死
(AMI)的一种严重并发症，好发于左心室心尖部，少数







病死率是无 VA形成患者的 7 倍多［2］。VA 按发生时





瘤(LVA) ，由 MI 所引起的占 90%以上，其他如心肌
·556·心血管病学进展 2018年 7月第 39卷第 4期 Adv Cardiovasc Dis，July 2018，Vol．39，No．4
cnki．
